Dexpramipexole

Drug Profile

Dexpramipexole

Alternative Names: BIIB 050; KNS-760704; RPPX

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator University of Virginia
  • Developer Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
  • Class Antiparkinsonians; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome

Most Recent Events

  • 04 Jan 2017 Knopp Biosciences received patent protection entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils” for dexpramipexole in USA
  • 03 Dec 2016 Efficacy and adverse events data from a phase II trial in Hypereosinophilic syndrome presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 03 Dec 2016 Knopp Biosciences completes enrolment in its phase II trial for Hypereosinophilic Syndrome in USA (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top